Results 101 to 110 of about 19,745 (243)

The receptor-toxin-antibody interaction: Mathematical model and numerical simulation [PDF]

arXiv, 2012
A reaction-diffusion model of receptor-toxin-antibody (RTA) interaction is studied numerically. The protective properties of an antibody against a given toxin are evaluated for a spherical cell placed into a toxin-antibody solution. The selection of parameters for numerical simulation approximately corresponds to the practically relevant values ...
arxiv  

IQ Survey Results on Current Industry Practices: Part 2—Quantitative Evaluations of Immunogenicity Assessment

Clinical Pharmacology &Therapeutics, EarlyView.
All biotherapeutics have the potential to induce an immunogenic response and generate anti‐drug antibodies (ADAs), especially when administered as multiple doses over prolonged periods. However, a clinically meaningful effect of ADAs can be difficult to identify to communicate the impact of immunogenicity on drug exposure, safety and efficacy outcomes ...
Susan Richards, Insa Winzenborg, Doreen Luedtke, Tao Niu, Lora Hamuro, Karey Kowalski, Jocelyn H. Leu, Jianning Yang, Vaishnavi Ganti, Indranil Bhattacharya, Ivelina Gueorguieva, Nael Mostafa, Christine Grimaldi, Benjamin Wu   +13 more
wiley   +1 more source

An Engineered Mouse Model That Generates a Diverse Repertoire of Endogenous, High-Affinity Common Light Chain Antibodies

Antibodies
Bispecific antibodies have gained increasing popularity as therapeutics as they enable novel activities that cannot be achieved with monospecific antibodies.
Yinghui Rong, I-Ling Chen, Lance Larrabee, Manali S. Sawant, Germaine Fuh, Patrick Koenig   +5 more
doaj   +1 more source

Model‐Informed Drug Development Applications and Opportunities in mRNA‐LNP Therapeutics

Clinical Pharmacology &Therapeutics, EarlyView.
The utilization of lipid nanoparticles (LNP) for encapsulating mRNA has revolutionized the field of therapeutics, enabling the rapid development of COVID‐19 vaccines and cancer vaccines. However, the clinical development of mRNA‐LNP therapeutics faces numerous challenges due to their complex mechanisms of action and limited clinical experience.
Jiawei Zhou, Rohit Rao, Monica E. Shapiro, Nessy Tania, Cody Herron, Cynthia J. Musante, Jim H. Hughes   +6 more
wiley   +1 more source

A pivotal decade for bispecific antibodies?

mAbs
Bispecific antibodies (bsAbs) are a class of antibodies that can mediate novel mechanisms of action compared to monospecific monoclonal antibodies (mAbs). Since the discovery of mAbs and their adoption as therapeutic agents in the 1980s and 1990s, the development of bsAbs has held substantial appeal.
Marlena Surowka, Christian Klein
openaire   +3 more sources

Oncology Dose Optimization: Tailored Approaches to Different Molecular Classes

Clinical Pharmacology &Therapeutics, EarlyView.
Oncology dose optimization during the era of chemotherapy focused on identifying the maximum tolerated dose (MTD) for registrational trials, often resulting in significant toxicity. The advent of molecular targeted drugs and immunotherapies offers the potential to achieve similar efficacy with lower doses and fewer side effects, as maximal efficacy is ...
Jiawen Zhu, Amy Schroeder, Sabine Frank, Christophe Boetsch, Candice Jamois, Nastya Kassir, Koorosh Korfi, Elizabeth Punnoose, Anjali Vaze, Peter Trask, Pritti Gosai, Jane Fridlyand, Chunze Li   +12 more
wiley   +1 more source

Association of clonal haematopoiesis with heart failure incidence and outcomes: A systematic review and meta‐analysis

European Journal of Heart Failure, EarlyView.
Association of clonal haematopoiesis with heart failure incidence and outcomes: A systematic review and meta‐analysis. Clonal haematopoiesis and heart failure: a meta‐analysis. CH, clonal haematopoiesis; CI, confidence interval; HF, heart failure. [Correction added on 15 March 2025, after first online publication: The graphical image was corrected in ...
Paschalis Karakasis, Eleftheria Lefkou, Konstantinos Pamporis, Dimitrios Farmakis, Dimitrios Patoulias, Antonios P. Antoniadis, Stephane Heymans, Gerasimos Filippatos, Nikolaos Fragakis   +8 more
wiley   +1 more source

New bispecific antibodies in diffuse large B-cell lymphoma

Haematologica
The CD20xCD3 T-cell-engaging bispecific antibodies are a highly active new treatment option for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
Adrian G. Minson, Michael J. Dickinson
doaj   +1 more source

A REVIEW ON BISPECIFIC ANTIBODIES

, 2019
Antibodies are widely recognized for their therapeutic potential and subsequently have prompted a lot of interest into their development and application. The structure of monoclonal IgG antibody is represented, with the heavy chains in rose and the light chains in green.
openaire   +1 more source

A Comprehensive Review on Capillary Electrophoresis–Mass Spectrometry in Advancing Biomolecular Research

ELECTROPHORESIS, EarlyView.
ABSTRACT This review provides an in‐depth exploration of capillary electrophoresis–mass spectrometry (CE–MS) in biomolecular research from 2020 to 2024. CE–MS emerges as a versatile and powerful tool due to its numerous advantages, facilitating the analysis of various biomolecules, including proteins, peptides, oligonucleotides, and other metabolites ...
Laura Pont, María Vergara‐Barberán, Enrique Javier Carrasco‐Correa   +2 more
wiley   +1 more source